Advertisement

Management of Extended Criteria Donors

  • Norihide Fukushima
Chapter

Abstract

Only about 20 % of brain-dead donors in Japan have been fitted in a so-called standard criteria donor for all organs including the heart, lung, liver, pancreas, and kidney. Therefore, it is very important for us to maximize the number of transplantable organs in order to resolve severe donor shortage in Japan [1]. From these aspects, the purposes of donor management are not only to stabilize donor’s hemodynamics until organ procurement surgery but also to maximize donor organ availability and to improve function of extended criteria donor organs. If organ availability is increased, more patients can be saved by organ transplantation. Maximizing donor organ availability is also the last wish of donors and donor families. However, if a transplant recipient died due to a very marginal donor organ, the donor family feels the loss of their loved one again. Therefore, the prevention of primary graft dysfunction (PGD) is essential for the donor family as well as for recipients.

Full - scale donor management begins after the patient is pronounced brain dead and his or her family agrees to donate the organ(s), especially in Japan. In general, donor management is based on the treatment of cardiac and respiratory dysfunction resulting in the improvement of hemodynamics, oxygen supply, and finally other organ function. The targets of hemodynamic parameters are systemic blood pressure >90 mmHg, central venous pressure (CVP) of 6–10 mmHg, urine output of 100 mL/h (0.5–3 mL/kg/h), and heart rate of 80–120 beats/min. As organ procurement surgery begins within 12 h after full-scale donor management is started, it is very different from the usual intensive care to stabilize hemodynamics and to maintain and improve organ function as much as possible in a short period. Moreover, it is important for the physicians who perform donor management to recognize the pathophysiology of brain death from the beginning to completion period.

Keywords

Central Venous Pressure Brain Death Diabetes Insipidus Pulmonary Capillary Wedge Pressure Systemic Blood Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Fukushima N, Ono M, Nakatani T, et al. Strategies for maximizing heart and lung transplantation opportunities in Japan. Transplant Proc. 2009;41(1):273–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation. 2006;82(11):1396–401.PubMedCrossRefGoogle Scholar
  3. 3.
    Mascia L, Mastromauro I, Viverti S, et al. Management of optimize organ procurement in brain dead donors. Minerva Anestesiol. 2009;75:125–33.PubMedGoogle Scholar
  4. 4.
    Wood KE, Becker BN, McCartney JG, et al. Current concepts: care of potential organ donor. N Engl J Med. 2004;351:2730–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilhalem MJ, Pratschke J, Laskowski IA, et al. Brain death and its impact on the donor heart-lessons from animal models. J Heart Lung Transplant. 2000;19:414–8.CrossRefGoogle Scholar
  6. 6.
    Audibert G, Charpentier C, Sequim-Devaux C, et al. Improvement of donor myocardial function after treatment of autonomic storm during brain death. Transplantation. 2006;82:1031–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Ryan JB, Hicks M, Cropper JR, et al. Functional evidence of reversible ischemic injury immediately after the sympathetic storm associated with experimental brain death. J Heart Lung Trasnplant. 2003;22:922–8.CrossRefGoogle Scholar
  8. 8.
    Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;5(8):1336–41.CrossRefGoogle Scholar
  9. 9.
    Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant. 1998;17:423–9.PubMedGoogle Scholar
  10. 10.
    Pennefether SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59:58.CrossRefGoogle Scholar
  11. 11.
    Kinoshita Y, Okamoto K, Yahata K, et al. Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. Pathol Res Pract. 1990;186(1):173–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Iwai A, Sakano T, Uenishi M, et al. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. Transplantation. 1989;48(4):613–7.PubMedGoogle Scholar
  13. 13.
    Novitzky D, Wicomb WN, Cooper DKC, et al. Electrocardiographic, haemodynamic and endocrine changes occurring during experimental brain death in the chacma baboon. J Heart Transplant. 1984;4:63.Google Scholar
  14. 14.
    Wicomb WN, Cooper DKC, Lanza RP, et al. The effects of brain death and 24 hours storage by hypothermic perfusion on donor heart function in the pig. J Thorac Cardiovasc Surg. 1986;91:896.PubMedGoogle Scholar
  15. 15.
    Novitzky D, Wicomb WN, Cooper DKC, Tjaalgard MA. Improved cardiac function following hormonal therapy in brain dead pigs: relevance to organ donation. Cryobiology. 1987;24:1.PubMedCrossRefGoogle Scholar
  16. 16.
    Kutsogiannis DJ, Pagliarello G, Doig C, Ross H, Shemie SD. Medical management to optimize donor organ potential: review of the literature. Can J Anaesth. 2006;53(8):820–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Powner DJ, Hendrich A, Lagler RG, et al. Hormonal changes in brain dead patients. Crit Care Med. 1990;18:785.Google Scholar
  18. 18.
    Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? Transplantation. 1992;54:851.PubMedCrossRefGoogle Scholar
  19. 19.
    Randell TT, Hockerstedt KAV. Triiodothyronine treatment in brain-dead multiorgan donors. Transplantation. 1992;54:736.PubMedCrossRefGoogle Scholar
  20. 20.
    Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83:41.PubMedGoogle Scholar
  21. 21.
    Wheeldon DR, Potter CDO, Oduro A, et al. Transforming the “unacceptable” donor: outcomes from adoption of a standardized donor management technique. J Heart Lung Transplant. 1995;14:734.PubMedGoogle Scholar
  22. 22.
    Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid. 1997;7:139.PubMedCrossRefGoogle Scholar
  23. 23.
    Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg. 2001;136:1377–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation. 2002;106:836.PubMedCrossRefGoogle Scholar
  25. 25.
    Zaroff JG, Rosengard BR, Armstrong WF, et al. Maximizing use of organs recovered from the cadaver donor: cardiac recommendations. J Heart Lung Transplant. 2002;21:1153.CrossRefGoogle Scholar
  26. 26.
    Keller F, Hemmen T, Schoneshofer M, et al. Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. Transplantation. 1995;60:330.PubMedCrossRefGoogle Scholar
  27. 27.
    Conci F, Di Rienzo M, Castiglioni P. Blood pressure and heart rate variability and baroreflex sensitivity before and after brain death. J Neurol Neurosurg Psychiatry. 2001;71:621–31.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Rapenne T, Moreau D, Lenfant F, Boggio V, Cottin Y, Freysz M, et al. Could heart rate variability analysis become an early predictor of imminent brain death? A pilot study. Anesth Analg. 2000;91:329–36.PubMedGoogle Scholar
  29. 29.
    Fukushima N, Shirakura R, Nakata S, et al. Failure of rapid autonomic augmentation of cardiac performance in transplanted hearts. Transplant Proc. 1998;30(7):3344–6. No abstract available.PubMedCrossRefGoogle Scholar
  30. 30.
    D'Amico TA, Buchanan SA, Lucke JC, et al. The preservation of cardiac function after brain death: a myocardial pressure-dimension analysis. Surg Forum. 1990;41:277–9.Google Scholar
  31. 31.
    Sakagoshi N, Shirakura R, Nakano S, et al. Serial changes in myocardial beta-adrenergic receptor after experimental brain death in dogs. J Heart Lung Transplant. 1992;11:1054–8.PubMedGoogle Scholar
  32. 32.
    Fukushima N, Sakagoshi N, Ohtake S, et al. Effects of exogenous adrenaline on the number of the beta-adrenergic receptors after brain death in humans. Transplant Proc. 2002;34:2571–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Milano A, Livi U, Casula R, et al. Influence of marginal donors on early results after heart transplantation. Transplant Proc. 1993;25:3158.PubMedGoogle Scholar
  34. 34.
    Stoica SC, Satchithananda DK, Charman S, et al. Swan-Ganz catheter assessment of donor hearts: outcome of organs with borderline hemodynamics. J Heart Lung Transplant. 2002;21:615.PubMedCrossRefGoogle Scholar
  35. 35.
    Ranger GS. Antidiuretic hormone replacement therapy to prevent or ameliorate vasodilatory shock. Med Hypotheses. 2002;59(3):337–40.CrossRefGoogle Scholar
  36. 36.
    Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney patients. Lancet. 1998;352:1178.PubMedCrossRefGoogle Scholar
  37. 37.
    Marques RG, Rogers J, Chavin KD, et al. Does treatment of cadaveric organ donors with desmopressin increase the likelihood of pancreas graft thrombosis? Results of a preliminary study. Transplant Proc. 2004;36:1048.PubMedCrossRefGoogle Scholar
  38. 38.
    Hoefer D, Ruttmann-Ulmer E, Smits JM, Devries E, Antretter H, Laufer G. Donor hypo- and hypernatremia are predictors for increased 1-year mortality after cardiac transplantation. Transpl Int. 2010;23(6):589–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Therapeutics for End-Stage Organ DysfunctionOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations